USEFULNESS OF FIB-4 INDEX AND ALT AT 1 YEAR OF NUCLEOS(T) IDE ANALOG TREATMENT FOR PREDICTION OF HEPATOCELLULAR CARCINOMA IN CHRONIC HEPATITIS B PATIENTS

被引：0
|
作者：
Inoue, Jun [1 ]
Akahane, Takehiro [2 ]
Kobayashi, Tomoo [3 ]
Kimura, Osamu [4 ]
Sato, Kosuke [1 ]
Ninomiya, Masashi [1 ]
Iwata, Tomoaki [1 ]
Takai, Satoshi [5 ]
Kisara, Norihiro [6 ]
Sato, Toshihiro [7 ]
Nagasaki, Futoshi [8 ]
Miura, Masahito [9 ]
Nakamura, Takuya [10 ]
Umetsu, Teruyuki [11 ]
Sano, Akitoshi [1 ]
Tsuruoka, Mio [1 ]
Onuki, Masazumi [1 ]
Sawahashi, Satoko [1 ]
Niitsuma, Hirofumi [1 ]
Masamune, Atsushi [1 ]
机构：
[1] Tohoku Univ, Grad Sch Med, Sendai, Miyagi, Japan
[2] Japanese Red Cross Ishinomaki Hosp, Ishinomaki, Miyagi, Japan
[3] Tohoku Rosai Hosp, Sendai, Miyagi, Japan
[4] South Miyagi Med Ctr, Sendai, Miyagi, Japan
[5] Iwaki City Med Ctr, Iwaki, Fukushima, Japan
[6] Japan Community Hlth Care Org Sendai South Hosp, Sendai, Miyagi, Japan
[7] LC Clin, Sendai, Miyagi, Japan
[8] Sendai City Hosp, Sendai, Miyagi, Japan
[9] Omagari Kousei Med Ctr, Daisen, Akita, Japan
[10] Yamagata City Hosp Saiseikan, Yamagata, Japan
[11] Kesennuma City Hosp, Kesennuma, Miyagi, Japan
来源：
HEPATOLOGY | 2023年 / 78卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1450-C
引用
收藏
页码：S550 / S550
页数：1
相关论文
共 50 条
  • [21] Impact of FIB-4 index on HCC incidence during nucleos(t)ide analogue therapy in chronic hepatitis B patients: an analysis using time-dependent ROC
    Tada, Toshifumi
    Kumada, Takashi
    Toyoda, Hidenori
    Kobayashi, Natsuko
    Tsuji, Kunihiko
    Hiraoka, Atsushi
    Tanaka, Junko
    HEPATOLOGY, 2016, 64 : 896A - 896A
  • [22] Stratification of hepatocellular carcinoma risk through modified FIB-4 index in chronic hepatitis B patients on entecavir therapy
    Wang, Hung-Wei
    Lai, Hsueh-Chou
    Hu, Tsung-Hui
    Su, Wen-Pang
    Lu, Sheng-Nan
    Lin, Chia-Hsin
    Hung, Chao-Hung
    Chuang, Po-Heng
    Wang, Jing-Houng
    Lee, Mei-Hsuan
    Chen, Chien-Hung
    Peng, Cheng-Yuan
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 (02) : 442 - 449
  • [23] Circulating thrombospondin 2 as a predictor of hepatocellular carcinoma in hepatitis B patients undergoing nucleos(t)ide analog therapy
    Okumura, Taiki
    Kimura, Takefumi
    Ichikawa, Yuki
    Iwadare, Takanobu
    Wakabayashi, Shun-ichi
    Kobayashi, Hiroyuki
    Yamashita, Yuki
    Uchida, Takuro
    Pydi, Sai P.
    Tanaka, Naoki
    Umemura, Takeji
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [24] THE HEPATOCELLULAR CARCINOMA RISK FACTOR DURING NUCLEOS(T)IDE ANALOGUES THERAPY ON TREATMENT NAIVE CHRONIC HEPATITIS B PATIENTS
    Kaneko, Shun
    Kurosaki, Masayuki
    Joko, Kouji
    Marusawa, Hiroyuki
    Kondo, Masahiko
    Kojima, Yuji
    Uchida, Yasushi
    Kimura, Hiroyuki
    Fujii, Hideki
    Akahane, Takehiro
    Yagisawa, Hitoshi
    Kusakabe, Atsunori
    Kobashi, Haruhirko
    Abe, Takehiko
    Yoshida, Hideo
    Ogawa, Chikara
    Furuta, Koichiro
    Tamaki, Nobuharu
    Tsuji, Keiji
    Matsushita, Tomomichi
    Hasebe, Chitomi
    Izumi, Namiki
    HEPATOLOGY, 2021, 74 : 464A - 465A
  • [25] Peginterferon Is Superior to Nucleos(t)ide Analogues for Prevention of Hepatocellular Carcinoma in Chronic Hepatitis B
    Liang, Kung-Hao
    Hsu, Chao-Wei
    Chang, Ming-Ling
    Chen, Yi-Cheng
    Lai, Ming-Wei
    Yeh, Chau-Ting
    JOURNAL OF INFECTIOUS DISEASES, 2016, 213 (06): : 966 - 974
  • [26] PEGINTERFERON IS SUPERIOR TO NUCLEOS(T)IDE ANALOGS FOR PREVENTION OF HEPATOCELLULAR CARCINOMA IN CHRONIC HEPATITIS B
    Liang, K. -H.
    Hsu, C. -W.
    Chang, M. -L.
    Chen, Y. -C.
    Lai, M. -W.
    Yeh, C. -T.
    JOURNAL OF HEPATOLOGY, 2015, 62 : S556 - S556
  • [27] High percentage atypical hepatocellular carcinoma in chronic hepatitis B patients treated with nucleos(t)ide analogs
    Lin, Ching-Chung
    Bair, Ming-Jong
    Liu, Chia-Yuan
    Lin, Ze-Yu
    Chen, Chih-Jen
    Chen, Ming-Jen
    Chu, Cheng-Hsin
    Wang, Horng-Yuan
    Shih, Shou-Chuan
    Wang, Tsang-En
    MEDICINE, 2019, 98 (01) : E13818
  • [28] On-Treatment Changes in FIB-4 and 1-Year FIB-4 Values Help Identify Patients with Chronic Hepatitis B Receiving Entecavir Therapy Who Have the Lowest Risk of Hepatocellular Carcinoma
    Wang, Hung-Wei
    Lai, Hsueh-Chou
    Hu, Tsung-Hui
    Su, Wen-Pang
    Lu, Sheng-Nan
    Lin, Chia-Hsin
    Hung, Chao-Hung
    Chuang, Po-Heng
    Wang, Jing-Houng
    Lee, Mei-Hsuan
    Chen, Chien-Hung
    Peng, Cheng-Yuan
    CANCERS, 2020, 12 (05)
  • [29] Secondary prevention for hepatocellular carcinoma in patients with chronic hepatitis B: are all the nucleos(t)ide analogues the same?
    Yip, Terry Cheuk-Fung
    Lai, Jimmy Che-To
    Wong, Grace Lai-Hung
    JOURNAL OF GASTROENTEROLOGY, 2020, 55 (11) : 1023 - 1036
  • [30] Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: A systematic review
    Papatheodoridis, George V.
    Lampertico, Pietro
    Manolakopoulos, Spilios
    Lok, Anna
    JOURNAL OF HEPATOLOGY, 2010, 53 (02) : 348 - 356
12345